Wave Life Sciences' PRISM platform combines stereopure nucleic acid chemistry with ADAR-recruiting AIMers for therapeutic RNA editing in humans.
Wave Life Sciences' PRISM platform is a modular RNA medicines toolkit that includes RNA editing (AIMers), splicing, RNA interference, and antisense silencing. Its ADAR-recruiting RNA editing oligonucleotides achieved first-in-human proof-of-mechanism for WVE-006 in alpha-1 antitrypsin deficiency.
The platform leverages proprietary PN chemistry, stereochemistry, and the N3U AIMer modification to enable durable, subcutaneously delivered RNA editing without altering genomic DNA.
Korro Bio's OPERA platform uses engineered oligonucleotides to make precise RNA edits, co-opting endogenous ADAR to correct disease-causing transcripts.
Korro Bio's OPERA platform uses engineered oligonucleotides to make precise RNA edits, co-opting endogenous ADAR to correct disease-causing transcripts.
